The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 17, 2025
Filed:
Jan. 18, 2018
Icahn School of Medicine AT Mount Sinai, New York, NY (US);
The Simons Center for Systems Biology AT the Institute for Advanced Study, Princeton, NJ (US);
Memorial Sloan Kettering Cancer Center, New York, NY (US);
Michael Laessig, New York, NY (US);
Marta Luksza, New York, NY (US);
Vinod P. Balachandran, New York, NY (US);
Arnold J. Levine, Princeton, NJ (US);
Jedd D. Wolchok, New York, NY (US);
Taha Merghoub, Jersey City, NJ (US);
Steven D. Leach, New York, NY (US);
Timothy A. Chan, New York, NY (US);
Benjamin D. Greenbaum, New York, NY (US);
Michael Laessig, Cologne, DE;
[object Object];
Icahn School of Medicine at Mount Sinai, New York, NY (US);
The Simons Center for Systems Biology at the Institute for Advanced Study, Princeton, NJ (US);
Memorial Sloan Kettering Cancer Center, New York, NY (US);
Abstract
Systems and methods for determining the likely responsiveness of a human cancer subject to a checkpoint blockade immunotherapy regimen are provided. Sequencing reads are obtained from samples from the subject representative of the cancer. A human leukocyte antigen type and a plurality of clones is determined from the sequencing reads. For each clone, an initial frequency Xin the one or more samples is determined and a corresponding clone fitness score of the clone is computed, thereby computing clone fitness scores. Each such fitness score is computed by identifying neoantigens in the respective clone, computing a recognition potential for each neoantigen, and determining the corresponding clone fitness score of the respective clone as an aggregate of these recognition potentials. A total fitness, quantifying the likely responsiveness of the subject to the regimen, is computed by summing the clone fitness scores across the plurality of clones.